Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815522) titled 'Abiraterone With Dalpiciclib in Salivary Gland Carcinoma' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Condition:
Salivary Gland Carcinoma
Intervention:
Drug: abiraterone combined with dalpiciclib
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 36
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/...